Pelvis plus prostate radiation therapy and the risk of death in men with newly diagnosed node-positive prostate cancer
Mené sur 721 patients atteints d'un cancer non métastatique de la prostate traité par hormonothérapie avec ou sans radiothérapie (âge médian : 66 ans ; durée médiane de suivi : 17 mois), cet essai évalue, en fonction du stade ganglionnaire de la maladie, la survie des patients puis l'effet de la radiothérapie sur le taux de survie sans échec
Both single-institutional retrospective series and a multi-institutional observational study1,2 find a significant association between a reduced risk of death and treatment of node-positive prostate cancer using both external-beam radiation treatment (EBRT) of the prostate and pelvic lymph nodes (LNs) and androgen deprivation therapy (ADT) compared with ADT alone. However, whether this association is causal remains unanswered and requires testing in a prospective randomized trial. In this issue of JAMA Oncology, James and colleagues3 use data from the control arm in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) Trial to investigate this issue.
JAMA Oncology , commentaire, 2014